Objective This study evaluated the characteristics of new users of sodium glucose co-transporter 2 inhibitors (SGLT2i) in clinical practice to assess the applicability of the findings from clinical trials (Empagliflozin. Cardiovascular Outcomes and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial. Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 trial. Canagliflozi... https://yeswellneses.shop/product-category/arthritis/